Allergy Therapeutics (LON:AGY) Issues Quarterly Earnings Results

Allergy Therapeutics (LON:AGY) released its quarterly earnings data on Monday. The company reported GBX (0.23) ($0.00) EPS for the quarter, Digital Look Earnings reports. Allergy Therapeutics had a negative net margin of 72.86% and a negative return on equity of 266.59%.

Allergy Therapeutics Stock Performance

Allergy Therapeutics stock opened at GBX 5.92 ($0.08) on Wednesday. The firm has a market capitalization of £290.97 million, a PE ratio of -5.71, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40. Allergy Therapeutics has a one year low of GBX 2.65 ($0.03) and a one year high of GBX 8 ($0.10). The stock’s 50 day moving average price is GBX 6.57 and its 200 day moving average price is GBX 5.92. The company has a debt-to-equity ratio of 835.48, a quick ratio of 1.48 and a current ratio of 1.63.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.